MENLO PARK, Calif. and SINGAPORE and CAMBRIDGE, Mass., Aug. 25, 2022 /PRNewswire/ -- BelleTorus Corporation ("Belle.ai") and ASLAN Pharmaceuticals (Nasdaq:ASLN), today announced that ASLAN has licensed belleStudy™ digital image capture software in support of ASLAN's clinical trials for atopic dermatitis (AD) across several global sites. ASLAN will make the image capture software component of belleStudy™ available to all investigators of TREK-AD, its ongoing global phase 2b trial of eblasakimab, expected to generate topline data in the first half of 2023.
Read more at prnewswire.comASLAN PHARMACEUTICALS SIGNS LICENSE AGREEMENT WITH BELLE.AI TO USE BELLESTUDY™ IMAGE CAPTURE SOFTWARE IN ATOPIC DERMATITIS CLINICAL TRIALS
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Chipset%20held%20over%20rush%20hour%20traffic%20by%20Jae%20Young%20Ju%20via%20iStock.jpg)
/Meta%20by%20creativeneko%20via%20Shutterstock.jpg)
/Tesla%20charging%20station%20black%20background%20by%20Blomst%20via%20Pixabay.jpg)